Lonza Group Ltd ( (CH:LONN) ) has issued an update.
Lonza Group Ltd has implemented a new simplified and streamlined operating model as part of its One Lonza vision, effective immediately. This restructuring replaces the previous divisional structure with three CDMO Business Platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities, aimed at enhancing customer experience and scalability for future growth. The reorganization is expected to empower key functions, improve execution capabilities, and maintain the company’s leadership in the healthcare CDMO market.
More about Lonza Group Ltd
Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs) dedicated to serving the healthcare industry. The company operates globally, collaborating with pharmaceutical and biotech companies to transform innovative ideas into viable therapies. Lonza’s offerings include cutting-edge science, smart technology, and lean manufacturing, generating significant sales and EBITDA in 2024.
YTD Price Performance: 1.19%
Average Trading Volume: 162,982
Technical Sentiment Signal: Sell
Current Market Cap: CHF39.42B
Learn more about LONN stock on TipRanks’ Stock Analysis page.